Completed PHASE1 INTERVENTIONAL 1-arm NCT00958724

Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors

A Phase 1 Study Of Neratinib (HKI-272) In Combination With Vinorelbine In Japanese Subjects With Advanced Or Metastatic Solid Tumors

Sponsor: Puma Biotechnology, Inc.

Conditions Advanced Malignant Solid Tumors

Interventions Neratinib Vinorelbine

Updated 9 times since 2017 Last updated: Apr 24, 2018 Started: Jul 31, 2009 Primary completion: Apr 30, 2010 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00958724, this PHASE1 trial focuses on Advanced Malignant Solid Tumors and remains completed. Sponsored by Puma Biotechnology, Inc., it has been updated 9 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1
Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jul 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Jun 2018 — Jul 2018 [monthly]

Completed PHASE1
Mar 2018 — Jun 2018 [monthly]

Completed PHASE1
Feb 2017 — Mar 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Puma Biotechnology, Inc.

Data source: Puma Biotechnology, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shizuoka, Japan
• Tokyo, Japan